Is HSDB 7317 Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use HSDB 7317? Is HSDB 7317 safe for nursing mother and child? Does HSDB 7317 extracts into breast milk? Does HSDB 7317 has any long term or short term side effects on infants? Can HSDB 7317 influence milk supply or can HSDB 7317 decrease milk supply in lactating mothers?

• DrLact safety Score for HSDB 7317 is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of HSDB 7317 may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that HSDB 7317 may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using HSDB 7317 .
• It is recommended to evaluate the advantage of not breastfeeding while using HSDB 7317 Vs not using HSDB 7317 And continue breastfeeding.
• While using HSDB 7317 Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Statin pharmacologically acts by inhibiting cholesterol synthesis. Excretion into breast milk is non-significant. Its low oral biodisponibility makes absorption by the infant unlikely. Influence on alteration of breast milk fat composition is unknown. High amount of cholesterol is required by the infant to ensure appropriate development of nervous system, cell membranes and hormones or vitamin production. Avoiding use while exclusive breastfeeding would be advisable. Atorvastatin is probably safer because of a higher molecular weight that would interfer with excretion into breast milk. Pravastatin has also shown a low excretion. Simvastatin has the lowest oral biodisponibility. Interruption of drug hypercholesterolemia treatment while breastfeeding would probably not affect long-term outcome of the disease. A hypolipidemic diet should be followed.

Levels of HSDB 7317 in milk are low, but no relevant published information exists with its use during breastfeeding. The consensus opinion is that women taking a statin should not breastfeed because of a concern with disruption of infant lipid metabolism. However, others have argued that children homozygous for familial hypercholesterolemia are treated with statins beginning at 1 year of age, that statins have low oral bioavailability, and risks to the breastfed infant are low, especially with HSDB 7317 and pravastatin.[1] Until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.